InflaRx N.V. presented multiple posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting on March 7, 2025, detailing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). The presentations included clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses.
Safety data from a Phase 2a PG study showed vilobelimab was well-tolerated across all doses, with adverse events mostly mild to moderate and no specific safety concerns. PK/PD data in PG indicated an approximate 90% reduction in C5a concentrations by Day 15, sustained in higher dose groups, suggesting doses greater than 1600mg bi-weekly are needed for C5a suppression.
In HS, a post-hoc analysis of the Phase 2b SHINE trial demonstrated a significantly greater reduction in mean draining tunnel (dT) count with vilobelimab, at -63.2% versus -18.0% for placebo. Vilobelimab also showed a 3.1x relative responder improvement in complete resolution of dTs (dT100) compared to placebo, with rates of 40.9% versus 13.0%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.